New drug cocktail targets rare eye cancer
NCT ID NCT05282901
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial tests whether combining pembrolizumab (an immunotherapy) with lenvatinib (a targeted therapy) can control metastatic uveal melanoma, a rare eye cancer that has spread. About 51 adults are enrolled in two groups: those who have never taken Tebentafusp and those who have. The main goal is to see how long the cancer stays under control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- pembrolizumab and lenvatinib
- What this could lead to
- If successful, this combination could offer a new treatment option for metastatic uveal melanoma, a rare eye cancer with limited therapies.
- What could go wrong
- This is a small, early-phase trial with only 51 participants and no comparison group. The combination may not improve survival and could cause side effects like high blood pressure or immune reactions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC UVEAL MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Institut Curie
Paris, 75005, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug shrink Hard-to-Treat eye cancer?
- Double immunotherapy plus liver blockade targets eye cancer that spreads
- First-in-Class cancer drug targets Hard-to-Treat tumors
- Engineered immune cells take on Hard-to-Treat melanoma
- Immune cell therapy shows promise against rare eye cancer
- Liver-Directed chemo shows promise for eye cancer metastases